Results from preclinical in vivo studies suggest that Clearmind’s drug candidate MEAI may be effective in treating: material Addiction without interrupting the natural reward process
TEL AVIV, VANCOUVER, ISRAEL/CANADA, January 17, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or “Company”), a biotechnology company A company focused on discovering and developing new psychedelic-derived treatments to solve major untreated health problems today reveals the tremendous potential of MEAI and its effects on substances. published additional positive preclinical results in a series of ongoing research studies conducted to – use disorders (SUD). A recent in vivo study examined the effects of his MEAI on the natural reward processes associated with cocaine addiction.
The preclinical study was led by Professor Gal Yadid of the Gonda Comprehensive Brain Research Center, Bar-Ilan University, Israel. As previously announced (see press release dated August 24, 2022), Clearmind’s proprietary MEAI at his 5mg/kg dose showed the unique ability to reduce cocaine cravings, It may be the first dedicated cocaine addiction treatment.
Our most recent research study was designed to assess the effects of MEAI on natural rewards, as reward-based positive reinforcement is an evolutionary survival strategy shared across species. However, in drug addiction, reward-seeking becomes maladaptive, endangering survival. The aim of this in vivo study was to conclude whether MEAI uses the same mechanisms underlying both drug and natural reward (such as sucrose) seeking. Results show that natural reward is maintained in his MEAI-treated rats, thus indicating that the effect of her MEAI on drug-seeking is not related to the general reward system. .
“We are excited to continue to demonstrate positive results for our unique drug candidate, MEAI. There is currently no dedicated treatment, but I think Clearmind is leading the way in this area. ”
Professor Gal Yadid said: Empirical data indicate that MEAI is a potential treatment for cocaine addiction, especially his SUD. This observation is based on our experience and previous data testing different treatments for SUD. Further research is needed to better characterize the respondent population. “
About Clearmind Medicine
Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of new psychedelic-derived therapeutics to solve a wide range of underserved health problems, including alcohol use disorders. I guess. Its primary purpose is to research and develop psychedelic-based compounds and commercialize them as regulated drugs, foods, or supplements.
The company’s intellectual portfolio currently consists of seven patent families. The company intends to seek additional patents for its compounds whenever warranted, and remains opportunistic in acquiring additional intellectual property to build its portfolio.
Clearmind shares are listed on the Nasdaq and Canadian Stock Exchanges under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY”.
See below for more information. https://www.clearmindmedicine.com or contact:
Phone: (604) 260-1566
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expect”, “expect”, “intend”, “plan”, “believe”, “seek”, “estimate” and similar expressions or variations of such words are It is intended to identify forward-looking statements. For example, we use forward-looking statements in discussing the results of preclinical studies and conducting future studies, and that psychedelic-based treatments address a variety of mental health conditions, It has the potential to offer a dedicated solution. Forward-looking statements are based on management’s current expectations, beliefs and projections rather than historical facts, many of which are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from those expressed or indicated in the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For more information on the risks and uncertainties that affect us, please refer to our reports filed from time to time with the U.S. Securities and Exchange Commission (“SEC”). The company’s final prospectus filed with the SEC on November 16, 2022 (registration number 333-265900). To reflect changes in actual results, subsequent events or circumstances, changes in assumptions, or other factors affecting forward-looking information, except to the extent required by applicable securities laws. does not undertake any obligation to update any forward-looking statements. Even if we update one or more forward-looking statements, no inference should be taken that we will make additional updates with respect to it or any other forward-looking statement. References and links to websites are provided as a convenience, and information contained in such websites is not incorporated by reference into this press release. Clearmind is not responsible for the content of third party websites.